Abstract
Get full access to this article
View all access options for this article.
References
1.
Topol
E
. Post on X . March 28, 2025 , 9:31 p.m. ET. Available from: https://x.com/EricTopol/status/1905794894443974715 [Last accessed:
April 12 , 2025
].
2.Biotechnology Innovation Organization . BIO Statement on Resignation of Peter Marks from the FDA . March 29, 2025 . Available from: https://www.bio.org/press-release/bio-statement-resignation-peter-marks-fda [Last accessed:
April 12 , 2025
].
3.
Marks
P
. Resignation Letter to Sara Brenner, MD, MPH, Acting Commissioner of Food and Drugs. Posted on X by Stephanie Armour, KFF Health News Senior Correspondent . March 28, 2025 , 10:08 p.m. ET. Available from: https://x.com/StephArmour1/status/1905804198983188975 [Last accessed:
April 12 , 2025
].
4.
Faguy
A
. Top US Vaccine Official Forced to Resign, Reports Say . BBC News . March 28, 2025 . Available from: https://www.bbc.com/news/articles/cn8r87z8vl0o [Last accessed:
April 12 , 2025
].
5.Atsena Therapeutics . Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs . April 2, 2025 . Available from: https://atsenatx.com/press-release/atsena-therapeutics-announces-oversubscribed-150-million-series-c-financing-to-further-advance-ocular-gene-therapy-programs/ [Last accessed:
April 13 , 2025
].
6.
Philippidis
A
. From Tools to Trials: Editing Therapy Companies Pivot to Development . March 20, 2025 . Available from: https://www.genengnews.com/topics/genome-editing/from-tools-to-trials-editing-therapy-companies-pivot-to-development/ [Last accessed:
April 13 , 2025
].
7.Arbor Biotechnologies . Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics . March 18, 2025 . Available from: https://arbor.bio/arbor-biotechnologies-announces-73-9-million-series-c-financing-to-advance-novel-gene-editing-therapeutics/ [Last accessed:
April 13 , 2025
].
8.
Huffman
S
. Spark Therapeutics files notice to lay off 300 employees this year . Technical.ly ; April 4, 2025 . Available from: https://technical.ly/company-culture/spark-therapeutics-layoffs-philadelphia-roche/ [Last accessed:
April 13 , 2025
].
9.Epicrispr Biotechnologies . Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD . March 26, 2025 . Available from: https://epicrispr.com/epicrispr-biotechnologies-announces-fda-clearance-of-ind-application-for-epi-321-a-first-in-class-epigenetic-therapy-for-fshd/ [Last accessed:
April 13 , 2025
].
10.
Thomas
U
. Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients . Genetic Engineering & Biotechnology News ; March 27, 2025 . Available from: https://www.genengnews.com/topics/genome-editing/epicrispr-biotechnologies-to-begin-clinical-trials-for-its-lead-epigenetic-therapy-for-fshd-patients/ [Last accessed:
April 13 , 2025
].
11.
Kansteiner
F
. CDMO AmplifyBio Closes Doors Amid Tough Market for early-stage Cell and Gene Therapy Development . Fierce Pharma ; April 7, 2025 . Available from: https://www.fiercepharma.com/manufacturing/cdmo-amplifybio-closes-doors-amid-tough-market-early-stage-cell-and-gene-therapy [Last accessed:
April 13 , 2025
].
12.AmplifyBio website . Important Announcement: AmplifyBio Operations Closure . Available from: https://www.amplify-bio.com [Last accessed:
April 8 , 2025
].
13.
Hagel
J
. NC Officials Agree to Cancel Economic Incentives for Novartis, Citing Hiring slowness . WRAL News ; April 9, 2025 . Available from: https://www.wral.com/story/nc-officials-agree-to-cancel-economic-incentives-for-novartis-citing-hiring-slowness/21952251/ [Last accessed:
April 12 , 2025
].